Press Releases

Dipexium Pharmaceuticals to Hold Second Quarter 2016 Financial Results Conference Call on Thursday, August 4, 2016, at 8:30 a.m. ET

Download PDF

NEW YORK, July 28, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended June 30, 2016, on Thursday, August 4, 2016 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.

To participate by telephone, please dial 877-407-8012 (U.S. & Canada) or 412-902-1013 (International) five minutes prior to the start of the call.  A live and archived audio webcast of the conference call can be accessed through the Investor Relations section of the Company's website at under the IR Calendar tab. The archived webcast will remain available on the Company's website for 30 days following the call.

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide. Initially, Locilex is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Dipexium also considers Locilex to be a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds, infected animal bites, and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). For more information, visit

Company Contacts:

David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.

David Garrett
Vice President, Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.

© 2016 Dipexium Pharmaceuticals, Inc.  All rights reserved.

To view the original version on PR Newswire, visit:

SOURCE Dipexium Pharmaceuticals, Inc.